
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical cream containing selegiline hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing selegiline are listed in capsule, tablet and patch forms. No finished selegiline product of any kind is listed in cream form.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Selegiline hydrochloride is a monoamine oxidase type B (MAO-B) inhibitor taken by mouth that pharmacies may compound, including as transdermal gels, on prescription.
Selegiline hydrochloride is the hydrochloride salt of selegiline, a monoamine oxidase inhibitor (MAOI). At labeled doses it mainly blocks MAO type B, an enzyme that breaks down dopamine in the brain, and it may raise dopamine activity in other ways too. Manufactured products include selegiline hydrochloride capsules and tablets (ANDA) and Zelapar orally disintegrating tablets (NDA). These are labeled as an add-on for people with Parkinson's disease taking levodopa/carbidopa whose response to that therapy is getting worse. A related product, Emsam, is a selegiline (base) skin patch labeled for major depressive disorder in adults. A prescriber might order selegiline hydrochloride compounded as an oral liquid or a transdermal gel, or in a strength that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
The oral selegiline hydrochloride label has no boxed warning; the Emsam patch label carries a boxed warning for suicidal thoughts and behaviors with antidepressants. Do not take more than prescribed: at higher doses selegiline loses its selectivity, raising the risk of dangerous high blood pressure with tyramine-rich foods (the "cheese reaction"), and such reactions have also been reported at the recommended dose. Do not use it with meperidine, a contraindication often extended to other opioids. Serious reactions, including one death with a tricyclic antidepressant, have been reported when selegiline was combined with tricyclic antidepressants or SSRIs such as fluoxetine, sertraline and paroxetine; tell your prescriber about every medicine, including dextromethorphan. Dizziness or fainting on standing can occur. People with Parkinson's disease have a higher melanoma risk, so ask about skin checks. Your levodopa dose may need lowering. Human milk data are lacking per the label, and LactMed says another drug may be preferred while breastfeeding. Talk to your prescriber or pharmacist about side effects.
Selegiline is an irreversible MAO-B inhibitor; per the Apotex label, MAO-B selectivity may not be absolute even at the recommended dose and diminishes as dose rises. Oral PK: absolute bioavailability unknown, with extensive presystemic metabolism in gut and liver; bioavailability rises 3 to 4 fold with food; major metabolites are N-desmethylselegiline (the only one with MAO-B activity), L-amphetamine and L-methamphetamine; mean half-life about 2 hours after one dose and about 10 hours at steady state, though irreversible inhibition means effect does not track plasma levels. Labeled indications: adjunct in Parkinson's disease with deteriorating response to levodopa/carbidopa (selegiline hydrochloride capsules, Apotex; Zelapar); major depressive disorder in adults (Emsam). Prescribers have ordered compounded selegiline hydrochloride in pluronic lecithin organogel for transdermal use; Allen notes it has been used in Parkinson's disease and other cognitive impairment, and that topical use avoids extensive first-pass effect (US Pharmacist 2013). StatPearls lists early Parkinson's disease and ADHD as off-label uses; these are not FDA-approved indications. Allow at least 14 days after stopping selegiline before a tricyclic or SSRI, and at least five weeks after stopping fluoxetine. Dosing is per prescriber. Monitor blood pressure, including orthostatic changes, and skin for melanoma.
Wash your hands. Apply the amount on your label to clean, dry skin and rub it in gently. For a metered pump, each press delivers a set amount; your label states how many presses. For transdermal creams, apply to the area your label names and let it dry before dressing. Wash your hands afterward and avoid skin-to-skin contact with others at the application site until it has absorbed. Do not apply to broken skin unless told to.
Creams are aqueous. Under USP <795>, a preserved cream usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Follow the storage line on your label, keep from freezing, keep out of reach of children, and discard after the beyond-use date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)